Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Heather G Jørgensen, Elaine K Allan, Joanne C Mountford, Linda Richmond, Simon Harrison, Moira A Elliott, Tessa L Holyoake

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.
Original languageEnglish
Pages (from-to)1140-6
Number of pages7
JournalExperimental Hematology
Volume33
Issue number10
DOIs
Publication statusPublished - 2005

Keywords

  • antigens
  • antineoplastic agents
  • apoptosis
  • bryostatins
  • drug antagonism
  • hematopoietic stem cells
  • leukemia
  • macrolides
  • piperazines
  • protein kinase C
  • pyrimidines

Cite this